Cargando…
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
BACKGROUND: Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and antitumor...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894203/ https://www.ncbi.nlm.nih.gov/pubmed/31801624 http://dx.doi.org/10.1186/s40425-019-0815-6 |
_version_ | 1783476341338800128 |
---|---|
author | Cohen, Ezra E. W. Pishvaian, Michael J. Shepard, Dale R. Wang, Ding Weiss, Jared Johnson, Melissa L. Chung, Christine H. Chen, Ying Huang, Bo Davis, Craig B. Toffalorio, Francesca Thall, Aron Powell, Steven F. |
author_facet | Cohen, Ezra E. W. Pishvaian, Michael J. Shepard, Dale R. Wang, Ding Weiss, Jared Johnson, Melissa L. Chung, Christine H. Chen, Ying Huang, Bo Davis, Craig B. Toffalorio, Francesca Thall, Aron Powell, Steven F. |
author_sort | Cohen, Ezra E. W. |
collection | PubMed |
description | BACKGROUND: Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and antitumor immunity. C-C chemokine receptor 4 (CCR4) is highly expressed in various solid tumor indications and associated with poor prognosis. This phase Ib, open-label study in patients with advanced solid tumors assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of utomilumab (PF-05082566), a human monoclonal antibody (mAb) agonist of the T-cell costimulatory receptor 4-1BB/CD137, in combination with mogamulizumab, a humanized mAb targeting CCR4 reported to deplete subsets of regulatory T cells (Tregs). METHODS: Utomilumab 1.2–5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2) was administered intravenously to 24 adults with solid tumors. Blood was collected pre- and post-dose for assessment of drug pharmacokinetics, immunogenicity, and pharmacodynamic markers. Baseline tumor biopsies from a subset of patients were also analyzed for the presence of programmed cell death-ligand 1 (PD-L1), CD8, FoxP3, and 4-1BB/CD137. Radiologic tumor assessments were conducted at baseline and on treatment every 8 weeks. RESULTS: No dose-limiting toxicities occurred and the maximum tolerated dose was determined to be at least 2.4 mg/kg per the time-to-event continual reassessment method. No serious adverse events related to either treatment were observed; anemia was the only grade 3 non-serious adverse event related to both treatments. Utomilumab systemic exposure appeared to increase with dose. One patient with PD-L1–refractory squamous lung cancer achieved a best overall response of partial response and 9 patients had a best overall response of stable disease. No patients achieved complete response. Objective response rate was 4.2% (95% confidence interval: 0.1–21.1%) per RECIST 1.1. Depletion of Tregs in peripheral blood was accompanied by evidence of T-cell expansion as assessed by T-cell receptor sequence analysis. CONCLUSIONS: The combination of utomilumab/mogamulizumab was safe and tolerable, and may be suitable for evaluation in settings where CCR4-expressing Tregs are suppressing anticancer immunity. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02444793. |
format | Online Article Text |
id | pubmed-6894203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68942032019-12-11 A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors Cohen, Ezra E. W. Pishvaian, Michael J. Shepard, Dale R. Wang, Ding Weiss, Jared Johnson, Melissa L. Chung, Christine H. Chen, Ying Huang, Bo Davis, Craig B. Toffalorio, Francesca Thall, Aron Powell, Steven F. J Immunother Cancer Research Article BACKGROUND: Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and antitumor immunity. C-C chemokine receptor 4 (CCR4) is highly expressed in various solid tumor indications and associated with poor prognosis. This phase Ib, open-label study in patients with advanced solid tumors assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of utomilumab (PF-05082566), a human monoclonal antibody (mAb) agonist of the T-cell costimulatory receptor 4-1BB/CD137, in combination with mogamulizumab, a humanized mAb targeting CCR4 reported to deplete subsets of regulatory T cells (Tregs). METHODS: Utomilumab 1.2–5 mg/kg or 100 mg flat dose every 4 weeks plus mogamulizumab 1 mg/kg (weekly in Cycle 1 followed by biweekly in Cycles ≥2) was administered intravenously to 24 adults with solid tumors. Blood was collected pre- and post-dose for assessment of drug pharmacokinetics, immunogenicity, and pharmacodynamic markers. Baseline tumor biopsies from a subset of patients were also analyzed for the presence of programmed cell death-ligand 1 (PD-L1), CD8, FoxP3, and 4-1BB/CD137. Radiologic tumor assessments were conducted at baseline and on treatment every 8 weeks. RESULTS: No dose-limiting toxicities occurred and the maximum tolerated dose was determined to be at least 2.4 mg/kg per the time-to-event continual reassessment method. No serious adverse events related to either treatment were observed; anemia was the only grade 3 non-serious adverse event related to both treatments. Utomilumab systemic exposure appeared to increase with dose. One patient with PD-L1–refractory squamous lung cancer achieved a best overall response of partial response and 9 patients had a best overall response of stable disease. No patients achieved complete response. Objective response rate was 4.2% (95% confidence interval: 0.1–21.1%) per RECIST 1.1. Depletion of Tregs in peripheral blood was accompanied by evidence of T-cell expansion as assessed by T-cell receptor sequence analysis. CONCLUSIONS: The combination of utomilumab/mogamulizumab was safe and tolerable, and may be suitable for evaluation in settings where CCR4-expressing Tregs are suppressing anticancer immunity. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02444793. BioMed Central 2019-12-04 /pmc/articles/PMC6894203/ /pubmed/31801624 http://dx.doi.org/10.1186/s40425-019-0815-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cohen, Ezra E. W. Pishvaian, Michael J. Shepard, Dale R. Wang, Ding Weiss, Jared Johnson, Melissa L. Chung, Christine H. Chen, Ying Huang, Bo Davis, Craig B. Toffalorio, Francesca Thall, Aron Powell, Steven F. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title_full | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title_fullStr | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title_full_unstemmed | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title_short | A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
title_sort | phase ib study of utomilumab (pf-05082566) in combination with mogamulizumab in patients with advanced solid tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894203/ https://www.ncbi.nlm.nih.gov/pubmed/31801624 http://dx.doi.org/10.1186/s40425-019-0815-6 |
work_keys_str_mv | AT cohenezraew aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT pishvaianmichaelj aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT sheparddaler aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT wangding aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT weissjared aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT johnsonmelissal aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT chungchristineh aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT chenying aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT huangbo aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT daviscraigb aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT toffaloriofrancesca aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT thallaron aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT powellstevenf aphaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT cohenezraew phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT pishvaianmichaelj phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT sheparddaler phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT wangding phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT weissjared phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT johnsonmelissal phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT chungchristineh phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT chenying phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT huangbo phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT daviscraigb phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT toffaloriofrancesca phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT thallaron phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors AT powellstevenf phaseibstudyofutomilumabpf05082566incombinationwithmogamulizumabinpatientswithadvancedsolidtumors |